PHAS
PhaseBio Pharmaceuticals, Inc. [PHAS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PHAS Stock Summary
In the News
PHAS Financial details
Company Rating
Neutral
Market Cap
0
Income
27.84M
Revenue
818K
Book val./share
-2.39
Cash/share
0.16
Dividend
-
Dividend %
-
Employees
60
Optionable
No
Shortable
Yes
Earnings
22 Mar 2023
P/E
-0.12
Forward P/E
-
PEG
0.01
P/S
-
P/B
-0.03
P/C
0.44
P/FCF
-
Quick Ratio
0.32
Current Ratio
0.47
Debt / Equity
-0.05
LT Debt / Equity
-0.01
-
-
EPS (TTM)
0.59
EPS next Y
-
EPS next Q
-
EPS this Y
-99.87%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
77.78%
EPS Q/Q
47.83%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
1.13%
Inst Trans
0.03%
ROA
-127%
ROE
26%
ROC
10.96%
Gross Margin
100%
Oper. Margin
-8474%
Profit Margin
-8637%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.041-4.08
52W High
-
52W Low
-
RSI
71
Rel Volume
4.79
Avg Volume
1.79M
Volume
8.56M
Perf Week
0%
Perf Month
312.35%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
2.86915
-
-
Volatility
0%, 0.03%
Prev Close
0%
Price
0.0701
Change
-13.14%
PHAS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.13 | 0.09 | 0.01 | 0 | |
| Net income per share | -0.91 | -4.49 | -1.43 | -3.39 | 0 | |
| Operating cash flow per share | -0.73 | -3.21 | -1.44 | -2.06 | -1.61 | |
| Free cash flow per share | -0.75 | -3.24 | -1.48 | -2.11 | -1.7 | |
| Cash per share | 1.19 | 11.5 | 2.69 | 0.97 | 1.42 | |
| Book value per share | -8.66 | 9.6 | 2.18 | -0.87 | -3.16 | |
| Tangible book value per share | -8.66 | 9.6 | 2.18 | -0.87 | -3.16 | |
| Share holders equity per share | -8.66 | 9.6 | 2.18 | -0.87 | -3.16 | |
| Interest debt per share | 0.48 | 2.15 | 0.57 | 0.47 | 0.27 | |
| Market cap | 56.26M | 16.39M | 167.99M | 97.63M | 76.73M | |
| Enterprise value | 58.33M | -37.14M | 108.66M | 81.64M | 42.77M | |
| P/E ratio | -5.49 | -0.69 | -4.28 | -0.99 | -585.39 | |
| Price to sales ratio | 0 | 24.54 | 71.15 | 305.09 | 7.08K | |
| POCF ratio | -6.81 | -0.96 | -4.24 | -1.63 | -1.62 | |
| PFCF ratio | -6.64 | -0.95 | -4.14 | -1.59 | -1.53 | |
| P/B Ratio | -0.58 | 0.32 | 2.8 | -3.87 | -0.82 | |
| PTB ratio | -0.58 | 0.32 | 2.8 | -3.87 | -0.82 | |
| EV to sales | 0 | -55.6 | 46.02 | 255.11 | 3.95K | |
| Enterprise value over EBITDA | -7.85 | 1.87 | -2.86 | -0.84 | 25.73 | |
| EV to operating cash flow | -7.06 | 2.18 | -2.74 | -1.36 | -0.9 | |
| EV to free cash flow | -6.88 | 2.16 | -2.68 | -1.33 | -0.85 | |
| Earnings yield | -0.18 | -1.45 | -0.23 | -1.01 | 0 | |
| Free cash flow yield | -0.15 | -1.05 | -0.24 | -0.63 | -0.65 | |
| Debt to equity | -0.03 | 0.15 | 0.25 | -0.48 | -0.08 | |
| Debt to assets | 0.19 | 0.12 | 0.18 | 0.24 | 0.13 | |
| Net debt to EBITDA | -0.28 | 2.7 | 1.56 | 0.17 | -20.42 | |
| Current ratio | 0.78 | 13.68 | 9.3 | 2.68 | 1.75 | |
| Interest coverage | -3.14 | -5.01 | -36.93 | -58.72 | 137.72 | |
| Income quality | 0.81 | 0.72 | 1.01 | 0.61 | 361.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 7.27 | 4.74 | 40.9 | 1.49 | |
| Research and developement to revenue | 0 | 23.14 | 13.09 | 225.28 | 9.43 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.03 | 0.01 | 0.02 | 0.02 | 0.06 | |
| Capex to revenue | 0 | -0.18 | -0.41 | -4.41 | -247.35 | |
| Capex to depreciation | -2.25 | -1.13 | -5.52 | -2.78 | -1.49 | |
| Stock based compensation to revenue | 0 | 0.5 | 0.6 | 6.99 | 209.4 | |
| Graham number | 13.32 | 31.16 | 8.37 | 8.14 | 0.56 | |
| ROIC | 0.1 | -0.33 | -0.54 | 6.71 | 0 | |
| Return on tangible assets | -0.73 | -0.38 | -0.48 | -1.96 | 0 | |
| Graham Net | -8.72 | 9.26 | 1.91 | -1.63 | -3.8 | |
| Working capital | -3.85M | 58.05M | 70.34M | 25.19M | 20.9M | |
| Tangible asset value | -97.42M | 50.93M | 59.98M | -25.2M | -93.03M | |
| Net current asset value | -97.77M | 50.53M | 56.31M | -35.41M | -104.79M | |
| Invested capital | -0.03 | 0.15 | 0.25 | -0.48 | -0.08 | |
| Average receivables | 0 | 116.5K | 733K | 616.5K | 0 | |
| Average payables | 431.5K | 1.12M | 2.36M | 3.3M | 8.12M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 127.31 | 190.62 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 4.19K | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 2.87 | 1.91 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0.09 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.11 | -0.47 | -0.65 | 3.91 | 0 | |
| Capex per share | -0.02 | -0.02 | -0.03 | -0.05 | -0.09 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.22 | 0.01 | 0 | 0 | 0 | |
| Net income per share | -0.6 | -0.66 | 1.82 | -0.23 | -0.34 | |
| Operating cash flow per share | -0.23 | -0.13 | -0.42 | -0.47 | -0.21 | |
| Free cash flow per share | -0.24 | -0.14 | -0.45 | -0.47 | -0.21 | |
| Cash per share | 1.34 | 1.17 | 0.87 | 0.38 | 0.16 | |
| Book value per share | -0.4 | -1.05 | -1.93 | -2.11 | -2.39 | |
| Tangible book value per share | -0.4 | -1.05 | -1.93 | -2.11 | -2.39 | |
| Share holders equity per share | -0.4 | -1.05 | -1.93 | -2.11 | -2.39 | |
| Interest debt per share | 0.24 | 0.21 | 0.15 | 0.14 | 0.11 | |
| Market cap | 178.51M | 149.42M | 125.62M | 64.2M | 29.5M | |
| Enterprise value | 125.29M | 102.85M | 91.67M | 52.35M | 27.07M | |
| P/E ratio | -1.56 | -1.17 | 0.36 | -1.42 | -0.44 | |
| Price to sales ratio | 17.27 | 446.04 | 795.07 | 548.7 | 141.85 | |
| POCF ratio | -16.1 | -24.37 | -6.28 | -2.81 | -2.83 | |
| PFCF ratio | -15.74 | -22.07 | -5.8 | -2.8 | -2.82 | |
| P/B Ratio | -9.31 | -2.97 | -1.35 | -0.63 | -0.25 | |
| PTB ratio | -9.31 | -2.97 | -1.35 | -0.63 | -0.25 | |
| EV to sales | 12.12 | 307.02 | 580.16 | 447.47 | 130.16 | |
| Enterprise value over EBITDA | -4.77 | -3.26 | 1.06 | -5.04 | -1.7 | |
| EV to operating cash flow | -11.3 | -16.77 | -4.58 | -2.29 | -2.6 | |
| EV to free cash flow | -11.05 | -15.19 | -4.23 | -2.28 | -2.59 | |
| Earnings yield | -0.16 | -0.21 | 0.7 | -0.18 | -0.57 | |
| Free cash flow yield | -0.06 | -0.05 | -0.17 | -0.36 | -0.35 | |
| Debt to equity | -0.59 | -0.19 | -0.08 | -0.07 | -0.05 | |
| Debt to assets | 0.11 | 0.13 | 0.13 | 0.18 | 0.24 | |
| Net debt to EBITDA | 2.03 | 1.48 | -0.39 | 1.14 | 0.15 | |
| Current ratio | 5.47 | 3.04 | 1.75 | 1.27 | 0.47 | |
| Interest coverage | -82.89 | -128.72 | -112.17 | -74.28 | -142.66 | |
| Income quality | 0.39 | 0.19 | -0.23 | 2.05 | 0.62 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.39 | 11.48 | -70.77 | 34.26 | 22.02 | |
| Research and developement to revenue | 2.65 | 74.82 | -472.47 | 122.53 | 100.67 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.1 | 0.08 | 0 | 0.01 | |
| Capex to revenue | -0.02 | -1.9 | -10.48 | -0.42 | -0.28 | |
| Capex to depreciation | -0.43 | -4.91 | -2.73 | -0.08 | -0.1 | |
| Stock based compensation to revenue | 0.07 | 2.15 | 0.95 | 5.1 | 3.44 | |
| Graham number | 2.32 | 3.96 | 8.91 | 3.32 | 4.28 | |
| ROIC | 3.62 | 0.66 | -1.03 | 0.12 | 0.15 | |
| Return on tangible assets | -0.28 | -0.41 | 1.45 | -0.29 | -0.76 | |
| Graham Net | -0.87 | -1.49 | -2.32 | -2.52 | -2.68 | |
| Working capital | 72.33M | 43.78M | 20.9M | 5.88M | -13.12M | |
| Tangible asset value | -19.18M | -50.33M | -93.03M | -102.4M | -117.4M | |
| Net current asset value | -31.31M | -62.81M | -104.79M | -113.49M | -128M | |
| Invested capital | -0.59 | -0.19 | -0.08 | -0.07 | -0.05 | |
| Average receivables | 9.2M | 9.2M | 0 | 0 | 0 | |
| Average payables | 4.43M | 5.74M | 10.55M | 9.67M | 6.55M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 160.19 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.56 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 1.5 | 0.63 | -0.94 | 0.11 | 0.14 | |
| Capex per share | -0.01 | -0.01 | -0.03 | 0 | 0 |
PHAS Frequently Asked Questions
What is PhaseBio Pharmaceuticals, Inc. stock symbol ?
PhaseBio Pharmaceuticals, Inc. is a US stock , located in Malvern of Pennsylvania and trading under the symbol PHAS
What is PhaseBio Pharmaceuticals, Inc. stock quote today ?
PhaseBio Pharmaceuticals, Inc. stock price is $0.0701 today.
Is PhaseBio Pharmaceuticals, Inc. stock public?
Yes, PhaseBio Pharmaceuticals, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.79M
- Employee 60
- CEO Mr. Jonathan Mow
- Headquarters Malvern,PENNSYLVANIA,US
- IPO Date 2018-10-18
-
Website
https://phasebio.com 
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
